Midazolam

# 1) Receptor-level action → clinical effects

**Primary:** **GABA-A positive allosteric modulator (benzodiazepine class).**

* Binds at the **benzodiazepine site** (α/γ interface) → **increases the frequency** of Cl⁻ channel opening **in the presence of GABA** → neuronal hyperpolarisation.

* **No direct gating** (unlike propofol/barbiturates at high dose): requires GABA to be present.

**Other receptor effects (minor):**

* Weak inhibition of some **nicotinic ACh** and **5-HT3** currents reported; clinically trivial.

* **Central** effects dominate: anxiolysis, sedation/hypnosis, **anterograde amnesia**, anticonvulsant, mild muscle relaxation.

**Clinical effects that matter**

* **CNS:** dose-dependent sedation → hypnosis; **anterograde amnesia**; anticonvulsant (useful in status epilepticus).

* **CVS:** usually modest ↓MAP (venodilation/sympathetic blunting), but can be **pronounced in hypovolaemia/poor EF/with opioids**.

* **Respiratory:** dose-dependent depression; **synergistic** with opioids/propofol → apnoea risk.

* **Delirium:** prolonged infusions rise risk of ICU delirium; prefer light/targeted use.

---

# 2) Vial strength, preparation & basic pharmacokinetics (+ disadvantages)

**Formulation & vials**

* Water-soluble **imidazo-benzodiazepine**: ring **open** (water-soluble) in acidic vial; ring **closes** at physiologic pH → lipophilic & fast CNS entry.

* Common vials/amps: **1 mg/mL** (2 mL) and **5 mg/mL** (1–10 mL); ICU syringes often **50 mg/50 mL** or **100 mg/100 mL**.

**PK you’ll feel at the bedside**

* **Onset (IV):** 1–3 min; **peak:** 3–5 min; **single-dose duration:** ~30–60 min (redistribution).

* **Distribution:** large Vd (↑ with obesity/critical illness).

* **Metabolism:** hepatic **CYP3A4/5** → **1-hydroxymidazolam** (active), then glucuronidation.

* **Elimination:** renal excretion of metabolites.

* **Context-sensitive half-time:** short after a bolus but **rises steeply with infusion duration**, especially with **renal failure** (active metabolite accumulates).

**Practical disadvantages (stemming from above)**

* **Accumulation** with prolonged infusion/obesity/hepatic-renal dysfunction → delayed wake-up.

* **ICU delirium** risk > propofol/dex; avoid routine deep benzo sedation.

* **Drug–drug variability** (CYP3A inhibitors/inducers).

---

# 3) Practical dosing

## A. Theatre/Procedural use

* **Premed/anxiolysis (IV):** **1–2 mg** (0.02–0.04 mg/kg) titrated slowly.

* **Induction (rare as sole agent):** **0.1–0.3 mg/kg IV**—often **not ideal** due to slow, unpredictable hypnosis and haemodynamic depression when combined with opioids.

* **Adjunct to induction/maintenance:** small **0.5–2 mg** increments for amnesia.

## B. ICU sedation (avoid routine deep benzo sedation; use when indicated)

**Indications:** short-term bridge when propofol/dex contraindicated; **status epilepticus**; severe **alcohol/benzodiazepine withdrawal**; need for strong amnesia (e.g., distressed ECMO patient when other options limited).

**Typical dosing (adult):**

* **Bolus:** 1–2 mg IV q2–3 min to effect (caution with opioids).

* **Infusion:** **0.02–0.1 mg/kg/h** (i.e., **0.3–1.7 mcg/kg/min**); some units go up to **0.2 mg/kg/h** short-term.

* **Titrate to RASS target**; schedule sedation holds; prefer **days → hours**, not days → **weeks**.

**Status epilepticus (when using midazolam infusion):**

* **Bolus 0.1–0.2 mg/kg**, then **0.05–0.2 mg/kg/h**, titrate to seizure suppression (EEG guided). Expect tolerance → escalating rates; consider alternative agents if refractory.

---

# 4) Special populations — dosing cautions

## Pregnancy

* Crosses placenta → **neonatal respiratory depression/hypotonia** possible; avoid in **1st trimester** if alternatives exist.

* For urgent indications (e.g., seizure control), use **lowest effective dose**; have neonatal team ready.

## Lactation

* Small amounts in milk; **generally compatible** with breastfeeding after single procedural doses (often advise a short 4–6 h pause if large doses). Clinical judgment/local policy.

## Hepatic impairment

* **CYP3A metabolism** reduced → **lower dose & slower titration**; expect prolonged effect. Monitor sedation depth closely.

## Renal impairment

* **Active glucuronide metabolite accumulates** → **prolonged sedation** even when parent drug is low. Prefer non-benzo regimens for long sedation; if used, **reduce rate** and watch for delayed wake-up.

## Obesity

* Larger Vd → accumulation with boluses/infusions.

* **Bolus to Lean/Adjusted BW**, then titrate to effect; keep infusion **as low and brief as possible**.

## Paediatrics

* **Premed (oral):** **0.5 mg/kg** (max ~20 mg).

* **Intranasal/buccal:** **0.2–0.3 mg/kg** for anxiolysis/seizures.

* **IV sedation:** **0.02–0.05 mg/kg** boluses; **infusion 0.02–0.1 mg/kg/h**.

* Neonates/infants: increased sensitivity; prefer minimal dosing and careful monitoring.

---

# 5) Drug interactions (clinically key)

* **CNS depressants (opioids, propofol, volatiles, alcohol):** **synergistic** respiratory/CVS depression → **halve doses**, give slowly, secure airway/monitoring.

* **CYP3A4/5 inhibitors** (e.g., **azoles**, **macrolides/clarithro-**, **protease inhibitors**, **diltiazem/verapamil**, grapefruit): ↑ levels → **oversedation/apnoea**.

* **CYP3A inducers** (e.g., **rifampicin**, **carbamazepine**, **phenytoin**, **St John’s wort**): ↓ effect → higher needs.

* **Valproate** may potentiate sedation; watch depth.

* **Ketoconazole + midazolam** (IV) is a classic severe interaction—avoid.

---

# 6) Significant complications & what to do

* **Respiratory depression / apnoea** (esp. with opioids/propofol): airway readiness, titrate slowly, capnography.

* **Hypotension** in hypovolaemia/poor EF: pre-empt with fluids/pressor support; avoid large boluses.

* **Paradoxical agitation/disinhibition** (1–10%): stop midazolam; small **flumazenil** (below) or switch agent.

* **Delirium** with prolonged ICU use: favour non-benzo sedation; daily awakening.

* **Prolonged coma after stopping** in renal/hepatic impairment/obesity: anticipate, check metabolites, supportive care.

**Reversal (Flumazenil):**

* **0.2 mg IV** over 15 s; repeat **0.1–0.2 mg** every minute to effect (commonly up to **1 mg**; max **3–5 mg**).

* **Cautions:** may precipitate **seizures** in chronic benzo users/TCAs overdose; effect may **wear off before midazolam** → monitor for **re-sedation**.

---

## Pocket viva line

*Midazolam is a benzodiazepine **GABA-A PAM** that increases opening **frequency** (needs GABA). Fast onset, strong **amnesia**, good anticonvulsant—but accumulates with **renal/hepatic dysfunction/obesity** via active metabolite, interacts via **CYP3A**, and combined with opioids can cause **apnoea**. ICU infusions 0.02–0.1 mg/kg/h—keep short; prefer non-benzo sedation when possible.*

---

Want me to convert this into a **one-page printable card** (with infusion quick-math and interaction red-flags) for your ICU pocket? And what’s your **next drug**—**ketamine**, **dexmedetomidine**, or a vasoactive (e.g., **norepinephrine**) next?